TOKENPOST
1 min read
Add as a preferred source on Google

Summit Says FDA Declined Ivonescimab-Chemotherapy Approval for Some Advanced Lung Cancer Patients

The FDA cited insufficient evidence that the treatment helps patients live longer.

By Riza Dagoc
Published
An infusion bag hangs beside an empty oncology treatment chair / TokenPost.ai
An infusion bag hangs beside an empty oncology treatment chair / TokenPost.ai

Summit Therapeutics said the U.S. Food and Drug Administration (FDA) declined its application to approve ivonescimab with chemotherapy for certain patients with advanced lung cancer.

Summit said the decision reflected insufficient evidence that the treatment helps patients live longer.

Riza Dagoc

Riza Dagoc reports on regulation, investing and the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…